Products & Services

Colorectal cancer organoids

Cellesce has initially focused on providing a range of ten colorectal cancer organoids. These reflect the genetic diversity found in the major colorectal cancer sub-types. Full gene sequencing, RNA expression and drug response data are provided for each organoid. These are now available in commercial quantities required for compound screening in drug discovery or large-scale genetics research.

Colorectal organoids

Example images of five of our ten colorectal organoid lines. Confocal images using 20X objective of Cell Insight Cx7. Organoids stained for nuclear (blue) and cytoskeletal (red) markers for imaging. Scale 50μm

  • Organoids provided in frozen cryovials, ready for seeding into assay format. Each vial contains c.500 data points*
  • Derived from patient tissue from a range of colorectal sites and selected by the TNM classification of malignant tumours
  • Analysed for key driver mutations, using the SureSeq™ Solid Tumour Panel from Oxford Gene Technology (OGT), including but not limited to: APC, BRAF, EGFR, HRAS, KRAS, PDGFR, PIK3CA, PTEN, TP53, VHL mutations
  • In-house characterisation against a number of known CRC targeting pharmacological agents
  • Varied morphologies and growth profiles

*Based on assays performed in 96 or 384 well format

Custom organoid expansion services

  • Expansion of your own organoid lines or line derivation from PDX tissue
  • Using your current protocols, Cellesce will work to determine optimum condiditons for expansion in our systems, before expanding and supplying back to you in your desired quantities

Coming soon

  • Wild type ‘normal’ colorectal lines, prostate, breast and organoids of other tissue types
  • We are also developing larger scale bioreactor systems to enable provision of significantly larger scale organoids
© Cellesce Ltd 2018